BORDEAUX MDS WINTER SCHOOL FOR YOUNG
|
|
- Jewel Gordon
- 6 years ago
- Views:
Transcription
1 BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen
2 MOTOR COMPLICATIONS Beginning of 1970s on-of syndrome was described (Markham 1974) Wearing off: short duration response Motor benefit within minutes after intake, lasts for a few hours Parallels the rise and fall of plasma-dopa Wearing off On-off: sudden change in motor capacity Unpredictable Apparently unrelated to L-dopa intake and plasma levels T. Henriksen Muenter, 1971
3 DEFINITIONS OF DYSKINESIAS Dyskinesiatype Clinical picture Duration On-off status Off -(period) dystonia Biphasic dyskinesia Dystonia Variable Off Chorea or ballistic Limited T. Henriksen Intermediate Peak dosedyskinesia Chorea Variable On Mouradian MM in Managing Advanced Parkinson s Disease: The role of continuous dopaminergic stimulation. Aquilonius and Lees (Ed)
4 Pre-clinical studies of motor complications Pulsatile levodopa treatment is a cause of motor complications Study Finding Juncos et al, day intermittent levodopa, but not continuous levodopa treatment, produced behavioural sensitisation in 6-OHDA rats Bibbiani et al, 2005 Continuous apomorphine infusion improved motor function in primates for up to 6 months without dyskinesias Intermittent apomorphine produced dyskinesias within 7-10 days of treatment Blanchet et al, 2001 Dyskinesias <10 days of intermittent dopaminergic treatment in MPTP-treated primates Only 3 of 6 primates developed dyskinesias with continuous dopaminergic stimulation, but complications diminished in intensity Schmidt et al, 2008 In unilateral 6-OHDA lesioned rats, pulsatile levodopa injections (1-2/day) caused contraversive rotations and AIMs Pulsatile (1-2/day) injections of the dopamine agonist rotigotine resulted in more contraversive rotations than a slow release formulation Stockwell et al, 2009 Continuous rotigotine delivery (via osmotic minipump) produces less dyskinesias than pulsatile rotigotine administration (twice daily) in MPTP-treated primates Stockwell et al, 2010 Switching from pulsatile levodopa or rotigotine administration to continuous rotigotine infusion reduced the severity and duration of dyskinesias in primates T. Henriksen Juncos JL, et al. Ann Neurol 1989;25(5): Bibbiani F, et al. Exp Neurol 2005;192(1):73-8. Blanchet PJ, et al. Adv Neurol 2001;86: Schmidt WJ, et al. J Neural Transmiss 2008;115(10): Stockwell KA, et al. Exp Neurol 2009;219(2): Stockwell KA, et al. Exp Neurol 2010;221(1):79-85.
5 POTENTIAL MECHANISMS UNDERLYING PULSATILE LEVODOPA-INDUCED DYSKINESIAS Large peaks-and-troughs of extracellular dopamine: Rise and decline of levodopa and dopamine levels in the striatal extracellular fluid correlate with the timing of AIMs Larger increases in striatal levodopa and dopamine in dyskinetic 6-OHDA lesioned rats than in non-dyskinetic animals Chronic levodopa treatment may alter dopamine regulation and metabolism in striatum and may lead to treatment-related adaptations T. Henriksen Serotonergic system: Treatment with serotonin autoreceptor agonists blunts the peak in extracellular dopamine levels in dyskinetic rats Removal of serotonin afferents blocks levodopa-induced dyskinesias in 6-OHDA lesioned rats Thus, dysregulated dopamine release from serotonergic neurons likely play a key role in dyskinesia development Cenci MA, Lundblad M. J Neurochem 2006;99(2): Lindgren H et al. J. Neurochem 2010;112(6): Carta M, et al. Brain 2007;130(7):
6 AETIOLOGY OF DYSKINESIAS: WHAT WE HAVE LEARNED FROM THE LABORATORY T. Henriksen Adapted from Thanvi B, et al. Postgrad Med J 2007;83:384-88
7 MOTOR FLUCTUATIONS Levodopacarbidopa intestinal gel (LCIG) Erratic gastric emptying Bloating Late on No on Hyperkinesias T. Henriksen Apomorphine DBS
8 MOTOR COMPLICATIONS IN PARKINSON S DISEASE Frequently develop following chronic pulsatile levodopa treatment Motor complications manifest as motor fluctuations and dyskinesias After 4 to 6 years of oral levodopa treatment: 12% to 60% of patients develop motor fluctuations 8% to 64% of patients develop dyskinesias After 9 to 15 years: 61% to 96% of oral levodopa-treated patients develop dyskinesias Risk factors: Levodopa exposure Duration Dosage Age of onset Gender Disease duration T. Henriksen Ahlskog JE and Muenter MD. Mov Disorder 2001;16: Encarnacion EV and Hauser RA. Eur Neurol 2008;60:57-66.
9 EVALUATION, HOW? Pt/carer information PD diary, patient/carer/staff Compliance Subjective errors due to difficulty differentiating between symptoms Lack sensitivity to detect sensitivity over time (Papapetropolis 2012) Clinical evaluation, observation Rating scales Historical information, recall bias Physical examination, limited snapshot Wearable motion sensors/mobile devices ACC Tremor Pen Smart Phone Parkison KinetiGraph GYRO EMG StepWatch Activity Monitor T. Henriksen
10 RATING SCALES Abnormal Involuntary Movement Scale (AIMS), focuses on anatomical distribution and intensity of dyskinesia Rush Dyskinesia Rating Scale (RDRS) focuses on objective assessments of functional disability during prescribed tasks Lang Fahn Scale (LF) focuses on patient perceptions Rating Unified Parkinson s Disease Scale (UPDRS) Part IV assesses historical information on dyskinesia duration and has an overall assessment of intensity. Scale Obeso Scale the dyskinesia rating protocol, recommended in the Core Assessment Program for Intracerebral Transplantation (CAPIT) later modification (CAP-SIT). Home-based patient-completed diaries with designations of dyskinesia that vary from scale to scale dyskinesia present vs absent, dyskinesia divided into troublesome and nontroublesome Parkinson Disease Dyskinesia Scale (PDD-26) patient self-assessment scale. The Unified Dyskinesia Rating Scale (UDysRS) combines patient-based assessments of dyskinesia with objective evaluations of disability and impairment from dyskinesias. T. Henriksen
11 PARKISON KINETIGRAPH (PKG) T. Henriksen
12 PATIENT DIARY T. Henriksen
13 MDS-UDYSRS T. Henriksen
14 ACKNOWLEDGEMENT This presentation incorporates the Unified Dyskinesia Rating Scale (UDysRS), which is owned and outlicensed by the International Parkinson and Movement Disorder Society (MDS). Permission to reproduce the UDysRS in this presentation was granted by MDS.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 MDS-UPDRS T. Henriksen
33
34
35
36
BORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS INFUSION THERAPIES IN PARKINSON S DISEASE Apomorphine, T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR FLUCTUATIONS
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationContinuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report
Acta Biomed 2017; Vol. 88, N. 2: 190-195 DOI: 10.23750/abm.v88i2.5038 Mattioli 1885 Case report Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and
More informationdipraglurant in Parkinson s disease
dipraglurant in Parkinson s disease broad potential for a novel mechanism January 2012 1 disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue,
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationEMERGING TREATMENTS FOR PARKINSON S DISEASE
EMERGING TREATMENTS FOR PARKINSON S DISEASE Katerina Markopoulou, MD, PhD Director Neurodegenerative Diseases Program Department of Neurology NorthShore University HealthSystem Clinical Assistant Professor
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for carbidopa
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationSPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS WELCOME AND INTRODUCTIONS
PARKINSON S DISEASE SPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS THURSDAY, MAY 11, 2017 WELCOME AND INTRODUCTIONS Stephanie Paul Vice President Development and Marketing American Parkinson
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationORIGINAL CONTRIBUTION. Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease
ORIGINAL CONTRIBUTION Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease A Clinical and Pharmacokinetic Study Fabrizio Stocchi, MD, PhD; Laura Vacca, MD, PhD;
More informationRole of Serotonin Neurons in the Induction of Levodopa- and Graft-Induced Dyskinesias in Parkinson s Disease
Movement Disorders Vol. 25, Suppl. 1, 2010, pp. S174 S179 Ó 2010 Movement Disorder Society Role of Serotonin Neurons in the Induction of Levodopa- and Graft-Induced Dyskinesias in Parkinson s Disease Manolo
More informationMechanisms of L-DOPA-induced dyskinesia in Parkinson s Disease M. Angela Cenci
Mechanisms of L-DOPA-induced Dyskinesia in Parkinson s Disease 1 Prof., MD, PhD Professor of Experimental Medical Research Basal Ganglia Pathophysiology Unit Lund University, Lund (Sweden) Parkinson s
More informationREFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Apokyn in the 8MM Parkinson s Disease
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationhome environments of patients
A mobile-based system can assess Parkinson s disease symptoms from home environments of patients Treatment of Parkinson s disease involves major challenges like the large within- and between-patient variability
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name Co-careldopa 2000mg/500mg intestinal gel (Duodopa, Solvay Pharmaceuticals)
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationREFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Parkinson s Disease in Japan Market The Parkinson
More informationKEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)?
KEY SUMMARY 1. Mirapexin /Sifrol (pramipexole*) is a selective non-ergot dopamine agonist approved as immediate release since 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationDeep Brain Stimulation: Patient selection
Deep Brain Stimulation: Patient selection Halim Fadil, MD Movement Disorders Neurologist Kane Hall Barry Neurology Bedford/Keller, TX 1991: Thalamic (Vim) DBS for tremor Benabid AL, et al. Lancet. 1991;337(8738):403-406.
More informationDeep Brain Stimulation. Is It Right for You?
Deep Brain Stimulation Is It Right for You? Northwestern Medicine Deep Brain Stimulation What is DBS? Northwestern Medicine Central DuPage Hospital is a regional destination for the treatment of movement
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationOptimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
EXPERT OPINION Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective David J Brooks Division of Neuroscience, Faculty
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationCell transplantation in Parkinson s disease
Cell transplantation in Parkinson s disease Findings by SBU Alert Published September 18, 2001 Revised November 7, 2003 Version 2 Technology and target group: In Parkinsons disease, the brain cells that
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationThe serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery.
The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery. Rylander, Daniella Published in: Parkinsonism & Related Disorders DOI: 10.1016/S1353-8020(11)70039-6 2012
More informationFOR PARKINSON S DISEASE XADAGO NEXT?
FOR PARKINSON S DISEASE XADAGO can increase your daily on time without troublesome dyskinesia 1 Please see the complete Important Safety Information on pages 12-13 and the accompanying full Prescribing
More informationREFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Sales for Parkinson s Disease in the US The Parkinson s disease market in the
More informationDifferent Dyskinesias in Parkinson s Disease and Their Relationship to Levodopa
EUROPEAN NEUROLOGICAL JOURNAL REVIEW ARTICLE Different Dyskinesias in Parkinson s Disease and Their Relationship to Levodopa Clare Loane, Paul Su and Marios Politis Affiliation: Centre for Neuroscience,
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationApomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease : an old drug revisited
Pérez Lloret, Santiago Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease : an old drug revisited Preprint del documento publicado en European Journal of Neurology,
More informationLong term motor complications of levodopa: clinical features, mechanisms, and management strategies
452 REVIEW Long term motor complications of levodopa: clinical features, mechanisms, and management strategies B R Thanvi, T C N Lo... Levodopa is the most effective symptomatic treatment of Parkinson
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationUnderstanding Parkinson s Disease Important information for you and your loved ones
Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationCLINICAL MANAGEMENT OF DRUG-INDUCED DYSKINESIA IN PARKINSON S DISEASE: WHY CURRENT APPROACHES MAY NEED TO BE CHANGED TO OPTIMISE QUALITY OF LIFE
CLINICAL MANAGEMENT OF DRUG-INDUCED DYSKINESIA IN PARKINSON S DISEASE: WHY CURRENT APPROACHES MAY NEED TO BE CHANGED TO OPTIMISE QUALITY OF LIFE *Jean-Francois Daneault, 1 Gloria Vergara-Diaz, 1,2 Sunghoon
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationREFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Duodopa in the 8MM Parkinson s Disease
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationAnnouncing FDA Approval of GOCOVRI TM
Announcing FDA Approval of GOCOVRI TM August 24, 2017 2017 Adamas Pharmaceuticals, Inc. All Rights Reserved. 1 Forward-looking Statements Statements contained in this presentation regarding expected future
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationTranscript. Welcome and Introductions. Stephanie Paul
Welcome and Introductions Transcript [Slide 1] Welcome everyone and thank you so much for joining us today. [Slide 2] My name is, and I m the Vice President of Development and Marketing at the American
More informationDopamine released from 5-HT terminals is the cause of L-DOPA-induceddyskinesiainparkinsonianrats
doi:10.1093/brain/awm082 Brain (2007), 130,1819^1833 Dopamine released from 5-HT terminals is the cause of L-DOPA-induceddyskinesiainparkinsonianrats Manolo Carta, 1,2 Thomas Carlsson, 2 Deniz Kirik 2
More informationContinuous intrajejunal levodopa-carbidopa intestinal gel in the treatment of patients with advanced Parkinson s disease effects on motor symptoms
Activitas Nervosa Superior Rediviva Volume 57 No. 3 2015 This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationPost- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. Cenci Nilsson, Angela; Lundblad, Martin Published in: Journal of Neurochemistry DOI: 10.1111/j.1471-4159.2006.04124.x Published: 2006-01-01
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationCurrent Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson s Disease
670 CNS & Neurological Disorders - Drug Targets, 2011, 10, 670-684 Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson s Disease M.A. Cenci *,1,
More informationClinical Study Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with 6-Month Followup
Parkinson s Disease Volume 2012, Article ID 910454, 4 pages doi:10.1155/2012/910454 Clinical Study Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationBuspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats
Pharmacological Reports 2011, 63, 908 914 ISSN 1734-1140 Copyright 2011 by Institute of Pharmacology Polish Academy of Sciences Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned
More informationMETHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE
METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE Madrid, 14 de noviembre de 2017 1. THE TEAM AND THE INSTITUTIONS BEHIND
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationBasal ganglia motor circuit
Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition
More informationParkinson s disease: diagnosis and current management
n DRUG REVIEW Parkinson s disease: diagnosis and current management Lucy Collins MPhil, Gemma Cummins MRCPI and Roger A Barker PhD, MRCP SPL Treatment for Parkinson s should be tailored to the needs of
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationOverview of Parkinson s disease Research at University of Colorado
Overview of Parkinson s disease Research at University of Colorado Brian D. Berman, MD, MS May 12, 2018 University of Colorado Movement Disorders Center Terminology Basic science pure/fundamental scientific
More informationClinical Study Impact of Duodopa on Quality of Life in Advanced Parkinson s Disease: A UK Case Series
Parkinson s Disease Volume 2013, Article ID 362908, 5 pages http://dx.doi.org/10.1155/2013/362908 Clinical Study Impact of Duodopa on Quality of Life in Advanced Parkinson s Disease: A UK Case Series T.
More informationUNDERSTANDING PARKINSON S DISEASE
UNDERSTANDING PARKINSON S DISEASE WHAT IS PARKINSON S DISEASE? A progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middleaged
More informationDARU Volume 13, No. 1,
DARU Volume 13, No. 1, 2005 23 COMPARISON BETWEEN BROMOCRIPTINE AND SELEGILINE IN TREATMENT OF PARKINSON ALIJAN AHMADI AHANGAR, ALI REZA SADRAIE, SEYED BEHNAM ASHRAF VAGHEFI, MIR SAID RAMESANI Department
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationSerotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson s disease patients
Research article Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson s disease patients Marios Politis, 1,2 Kit Wu, 2 Clare Loane, 1,2 David J. Brooks, 2,3 Lorenzo Kiferle,
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationA Four Point Plan for Enhanced Support for Parkinson s Disease In B.C.
A Four Point Plan for Enhanced Support for Parkinson s Disease In B.C. February 14, 2017 Executive Summary More than 13,300 British Columbians live with Parkinson s Disease (PD) and our aging population
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationEvidence compendium. Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease
Evidence compendium Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease CONTENTS Introduction... 4 Index of study summaries... 6 Parkinson s disease
More informationCh. 4: Movement Disorders
Ch. 4: Movement Disorders Hiral Shah, MD Parkinson s Disease and DOPA Cotzias GC, Van Woert MH, and Schiffer, LM. Aromatic Amino Acids and Modification of Parkinsonism. N Engl J Med 1967; 276: 374-379.
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Xenazine Page: 1 of 5 Last Review Date: June 12, 2014 Xenazine Description Xenazine (tetrabenazine)
More informationAmantadine Extended-Release. Gocovri, Osmolex ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.21 Subject: Amantadine ER Page: 1 of 5 Last Review Date: June 22, 2018 Amantadine Extended-Release
More information